Investor Presentation Q1-Q3 2020

21 Investor presentation First nine months of 2020 Novo Nordisk's opportunity is in the large unmet needs across all therapy areas in scope DIABETES -463 million -6% ~650 million OBESITY -2% Novo Nordisk® HAEMOPHILIA OTHER SERIOUS CHRONIC DISEASES ~0.5 million -25% People with diabetes People in good control People with obesity People medically treated People with haemophilia People being treated 80% of diagnosed NASH patients are obese and 35% have T2DM 70% of diabetes patients die from atherosclerotic CVD 40% of patients hospitalised for heart failure are diabetic Gro ~50% of the total CKD population suffers from diabetic nephropathy NASH: Non-alcoholic steatohepatitis, T2DM: Type 2 diabetes mellitus, CVD: Cardiovascular disease, CKD: Chronic kidney disease Source: International Diabetes Federation; Diabetes Atlas 9th Edition 2019, IQVIA MIDAS 2017, World Federation of Haemophilia - Annual survey 2018; Abera SF et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, 2017; Heart Disease and Stroke Statistics, American Heart Association, 2017; Williams CD et al. Prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilising ultrasound and liver biopsy, 2011; Addressing the global burden of chronic kidney disease through clinical and translational research, 2014

View entire presentation